Adalimumab Biosimilar Shows Equivalent Efficacy, Safety to Reference Humira for Psoriasis

October 20, 2021 06:30pm

Adalimumab biosimilar AVT02 exhibited comparative efficacy, safety, tolerability, and immunogenicity to the reference drug Humira in patients with moderate-to-severe chronic plaque psoriasis.

Dr Patty Taddei-Allen and Nick Page Discuss Precision Medicine and Health Disparities
Additional Data on Possible Chronic Cough Therapy Presented at CHEST 2021
Study Assesses Impact of Androgen Levels on Male Migraineurs
What We’re Reading: Unique Kidney Transplant Performed; OTC Hearing Aids Proposed; Fetal Sex, COVID-19 Response Linked